RxDoctor Payments Data

Brenda Latowsky, MD

Procedural Dermatology · Scottsdale, AZNPI 1306010467

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $116,562 of the $152,286 with a category attached, or 76.5%. AbbVie accounts for 75.6% of it on its own, with 38 other manufacturers making up the rest.

$152,286in general payments, 2019–2025

Across 572 payments — averaging $266.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$115K
  • Galderma Laboratories, L.p.$15K
  • Merz North America, Inc.$11K
  • Noctrix Health, Inc.$3K
  • Strata Skin Sciences, Inc.$3K
  • Revance Therapeutics, Inc.$1K
  • plus $4K from 33 others
$3,525,118in research payments, 2019–2025

Across 534 payments — averaging $6601.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$3M
  • Eli Lilly$144K
  • Endo Pharmaceuticals Inc.$134K
  • Galderma Laboratories, L.p.$107K
  • Dermavant Sciences, Inc.$41K
  • Arcutis Biotherapeutics, Inc.$26K
  • plus $45K from 6 others

What the payments were for

  • Consulting fees$116,56277%
  • Speaking & faculty fees$9,0196%
  • Travel & lodging$9,0276%
  • Food & beverage$17,49711%
  • Education$1820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$17,094
Medicare patients
80
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ValacyclovirValacyclovir Hcl21$150
Fluocinonide13$111
Doxycycline Hyclate17$106

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →